Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study.

Rebekka L Hansen,Tanja S Jørgensen,Alexander Egeberg,Nana A L Rosenø,Marie Skougaard,Zara R Stisen,Lene Dreyer,Lars-Erik Kristensen

Rheumatology (Oxford, England)（2023）

引用 0|浏览6

暂无评分

摘要

PsA patients receiving first- or second-line IL-17A inhibitors showed homogeneous baseline characteristics and similar adherence to therapy. Treatment failure of the first IL-17A inhibitor treatment should not preclude a second-line IL-17A inhibitor treatment.

查看译文

关键词

psoriatic arthritis, IL-17 inhibitors, adherence to therapy, switching

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要